133 related articles for article (PubMed ID: 37951220)
41. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
[TBL] [Abstract][Full Text] [Related]
42. Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease.
Srinivasan A; Vasudevan A; McFarlane A; Sparrow MP; Gibson PR; Van Langenberg DR
J Crohns Colitis; 2018 Feb; 12(3):280-288. PubMed ID: 29077839
[TBL] [Abstract][Full Text] [Related]
43. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
44. Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease.
Colman RJ; Tsai YT; Jackson K; Boyle BM; Noe JD; Hyams JS; D'Haens GRAM; van Limbergen J; Rosen MJ; Denson LA; Minar P
Inflamm Bowel Dis; 2021 Jun; 27(7):1045-1051. PubMed ID: 32944769
[TBL] [Abstract][Full Text] [Related]
45. De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months.
Little RD; Chu IE; Ward MG; Sparrow MP
Dig Dis Sci; 2022 Jan; 67(1):259-262. PubMed ID: 33763785
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.
Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y
J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255
[TBL] [Abstract][Full Text] [Related]
47. Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn's disease patients with secondary loss of response.
Kim ES; Kwon Y; Choe YH; Kim MJ
Therap Adv Gastroenterol; 2023; 16():17562848231170948. PubMed ID: 37168401
[TBL] [Abstract][Full Text] [Related]
48. Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.
Kopylov U; Al-Taweel T; Yaghoobi M; Nauche B; Bitton A; Lakatos PL; Ben-Horin S; Afif W; Seidman EG
J Crohns Colitis; 2014 Dec; 8(12):1632-41. PubMed ID: 25067824
[TBL] [Abstract][Full Text] [Related]
49. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
50. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
51. Adalimumab for maintenance of remission in Crohn's disease.
Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of adalimumab in comparison to infliximab for Crohn's disease: A systematic review and meta-analysis.
Yang HH; Huang Y; Zhou XC; Wang RN
World J Clin Cases; 2022 Jun; 10(18):6091-6104. PubMed ID: 35949827
[TBL] [Abstract][Full Text] [Related]
53. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.
Aguas M; Bastida G; Cerrillo E; Beltrán B; Iborra M; Sánchez-Montes C; Muñoz F; Barrio J; Riestra S; Nos P
World J Gastroenterol; 2012 Aug; 18(32):4391-8. PubMed ID: 22969204
[TBL] [Abstract][Full Text] [Related]
54. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
Duveau N; Nachury M; Gerard R; Branche J; Maunoury V; Boualit M; Wils P; Desreumaux P; Pariente B
Dig Liver Dis; 2017 Feb; 49(2):163-169. PubMed ID: 27899263
[TBL] [Abstract][Full Text] [Related]
55. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
Gonczi L; Kurti Z; Rutka M; Vegh Z; Farkas K; Lovasz BD; Golovics PA; Gecse KB; Szalay B; Molnar T; Lakatos PL
BMC Gastroenterol; 2017 Aug; 17(1):97. PubMed ID: 28789636
[TBL] [Abstract][Full Text] [Related]
56. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease.
Nakase H; Matsumoto T; Watanabe K; Hisamatsu T
J Gastroenterol; 2020 Sep; 55(9):824-832. PubMed ID: 32661927
[TBL] [Abstract][Full Text] [Related]
57. Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease.
Wong R; Qin L; Pan Y; Mahtani P; Longman R; Lukin D; Scherl E; Battat R
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959261
[TBL] [Abstract][Full Text] [Related]
58. Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease.
Srinivasan A; Gilmore R; van Langenberg D; De Cruz P
Therap Adv Gastroenterol; 2022; 15():17562848211070940. PubMed ID: 35126667
[TBL] [Abstract][Full Text] [Related]
59. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center.
Cohen RD; Lewis JR; Turner H; Harrell LE; Hanauer SB; Rubin DT
Inflamm Bowel Dis; 2012 Jan; 18(1):10-6. PubMed ID: 21456032
[TBL] [Abstract][Full Text] [Related]
60. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
deBruyn JC; Huynh HQ; Griffiths AM; Jacobson K; Mack D; Deslandres C; El-Matary W; Otley AR; Church PC; Lawrence S; Wine E; Sherlock M; Critch J; Benchimol EI; Jantchou P; Rashid M; Carroll MW; Bax K; Ricciuto A; Carman N; Walters TD;
Am J Gastroenterol; 2024 Mar; 119(3):565-575. PubMed ID: 37787642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]